Syncom Formulations India Ltd vs Vivimed Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 13.73 as of 30 Apr 15:30 . The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Vivimed Labs Ltd changed from 0 on March 2022 to 0 on March 2021 . This represents a CAGR of 0.0% over 5 years The Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Vivimed Labs Ltd changed from ₹ 119.81 crore on March 2022 to ₹ 131.42 crore on March 2021 . This represents a CAGR of 1.87% over 5 years The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The revenue of Vivimed Labs Ltd for the Dec '25 is ₹ 15.99 crore as compare to the Sep '25 revenue of ₹ 20.82 crore. This represent the decline of -23.2% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The ebitda of Vivimed Labs Ltd for the Dec '25 is ₹ -10.92 crore as compare to the Sep '25 ebitda of ₹ -0.74 crore. This represent the growth of 1375% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The net profit of Vivimed Labs Ltd changed from ₹ -15.25 crore to ₹ -16.55 crore over 7 quarters. This represents a CAGR of 4.79% The Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Vivimed Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

About Vivimed Labs Ltd

Vivimed Labs Limited was originally incorporated on September 22, 1988 as a private limited company in the name of Emgi Pharmaceuticals & Chemicals Pvt Ltd. On April 21, 1994, the company got converted into a public limited company and the name was changed to Emgi Pharmaceuticals & Chemicals Ltd and thereafter, the Company name was finally changed to Vivimed Labs Limited on April 22, 1997. The Company is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations.
The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing.
The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

FAQs for the comparison of Syncom Formulations (India) Ltd and Vivimed Labs Ltd

Which company has a larger market capitalization, Syncom Formulations (India) Ltd or Vivimed Labs Ltd?

Market cap of Syncom Formulations (India) Ltd is 1,290 Cr while Market cap of Vivimed Labs Ltd is 56 Cr

What are the key factors driving the stock performance of Syncom Formulations (India) Ltd and Vivimed Labs Ltd?

The stock performance of Syncom Formulations (India) Ltd and Vivimed Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syncom Formulations (India) Ltd and Vivimed Labs Ltd?

As of May 4, 2026, the Syncom Formulations (India) Ltd stock price is INR ₹13.73. On the other hand, Vivimed Labs Ltd stock price is INR ₹6.77.

How do dividend payouts of Syncom Formulations (India) Ltd and Vivimed Labs Ltd compare?

To compare the dividend payouts of Syncom Formulations (India) Ltd and Vivimed Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.